400 related articles for article (PubMed ID: 37497349)
21. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
[TBL] [Abstract][Full Text] [Related]
22. Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.
Jin J; Cong J; Lei S; Zhang Q; Zhong X; Su Y; Lu M; Ma Y; Li Z; Wang L; Zhu N; Yang J
Int Immunopharmacol; 2023 Aug; 121():110422. PubMed ID: 37302370
[TBL] [Abstract][Full Text] [Related]
23. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
24. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.
Gao B; Wang Y; Lu S
Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201
[TBL] [Abstract][Full Text] [Related]
25. Osteosarcoma: current status of immunotherapy and future trends (Review).
Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
[TBL] [Abstract][Full Text] [Related]
26. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract][Full Text] [Related]
27. A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma.
Yu B; Geng C; Wu Z; Zhang Z; Zhang A; Yang Z; Huang J; Xiong Y; Yang H; Chen Z
Sci Rep; 2024 Jan; 14(1):1308. PubMed ID: 38225273
[TBL] [Abstract][Full Text] [Related]
28. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
29. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
Pratt HG; Justin EM; Lindsey BA
Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
[TBL] [Abstract][Full Text] [Related]
30. T cell senescence: a new perspective on immunotherapy in lung cancer.
Huang M; Wang Y; Fang L; Liu C; Feng F; Liu L; Sun C
Front Immunol; 2024; 15():1338680. PubMed ID: 38415245
[TBL] [Abstract][Full Text] [Related]
31. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
32. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
[TBL] [Abstract][Full Text] [Related]
33. Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy.
Lin X; Wang X; Gu Q; Lei D; Liu X; Yao C
Biomed Mater; 2021 Mar; 16(4):. PubMed ID: 33601351
[TBL] [Abstract][Full Text] [Related]
34. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L
Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795
[TBL] [Abstract][Full Text] [Related]
35. Drugs in early clinical development for the treatment of osteosarcoma.
Heymann MF; Brown HK; Heymann D
Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
[TBL] [Abstract][Full Text] [Related]
36. A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma.
Shimizu T; Fuchimoto Y; Okita H; Fukuda K; Kitagawa Y; Ueno S; Kuroda T
J Pediatr Surg; 2018 Dec; 53(12):2460-2464. PubMed ID: 30266483
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
Zhao Y; Bai Y; Shen M; Li Y
Front Immunol; 2022; 13():992762. PubMed ID: 36225938
[TBL] [Abstract][Full Text] [Related]
38. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I; Verrecchia F; Crenn V; Redini F; Trichet V
Cells; 2020 Apr; 9(4):. PubMed ID: 32326444
[TBL] [Abstract][Full Text] [Related]
39. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
40. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
